Advertisement


Asaf Maoz, MD, on Pancreatic Surveillance Eligibility Criteria

2025 ASCO Annual Meeting

Advertisement

Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, discusses the sensitivity of age and family history criteria for determining eligibility for pancreatic cancer surveillance among individuals with a hereditary risk for the malignancy (Abstract 10500). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Our study looked at pancreatic cancer surveillance eligibility criteria among individuals who have a genetic risk of pancreatic cancer. Individuals who carry a pathogenic germline variant in a pancreatic cancer predisposition gene have an elevated risk of pancreatic cancer over the lifetime, and when surveillance has been done for these individuals, we have seen that this results in an earlier stage at diagnosis and improved survival compared with historical cohorts. However, not everyone who carries a pathogenic germline variant that predisposes them to pancreatic cancer has been eligible for pancreatic cancer surveillance and eligibility criteria have restricted eligibility based on age and a family history of pancreatic cancer. Our study was meant to look at the proportion of pathogenic germline variant carriers who would have been eligible for pancreatic cancer surveillance at the time of their pancreatic cancer diagnosis, and we leveraged a laboratory cohort to look at this question. We had over 11,000 individuals in the cohort and over 900 individuals who had a pathogenic germline variant that predisposes them to pancreatic cancer. Our results show that the age criteria for pancreatic cancer surveillance eligibility did very well, with over 85% of individuals who had a pathogenic germline variant and developed pancreatic cancer meeting the age eligibility criteria for surveillance. However, the family history criteria did poorly with only 22% of individuals who carry pathogenic germline variants and developing pancreatic cancer meeting the family history criteria when it's applicable. Our results suggest that having a family history of pancreatic cancer needs to be reevaluated as an eligibility criteria for pancreatic cancer surveillance among those who have a genetic risk of pancreatic cancer. We feel that our results support the recent removal of the family history requirement for pancreatic cancer surveillance eligibility for those who have germline pathogenic variants in BRCA2 and ATM.

Related Videos

Leukemia

William G. Wierda, MD, PhD, on Lisocabtagene Maraleucel in Relapsed/Refractory CLL: TRANSCEND CLL 004 

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses two abstracts on lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In Abstract 7037, liso-cel with ibrutinib demonstrated better efficacy and safety compared with liso-cel monotherapy, with statistically significant differences for complete response rate and overall response rate. In Abstract 7039, patients with R/R CLL/SLL who had received two or more prior lines of therapy had improved response, delayed progression, and prolonged survival with liso-cel compared with a real-world cohort treated with standard-of-care therapy. 

 

Leukemia

Mazyar Shadman, MD, PhD, on Doublet for Treatment-Naive CLL/SLL

Mazyar Shadman, MD, PhD, of Fred Hutchinson Cancer Center and the University of Washington, presents results from arm D of the SEQUOIA trial, which evaluated the combination of zanubrutinib and venetoclax in treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7009). 

Leukemia

Nitin Jain, MD, on Front-Line Therapies for CLL: Research Highlights From ASCO 2025

Nitin Jain, MD, Professor in the Department of Leukemia and Director of the Leukemia CAR-T Program at The University of Texas MD Anderson Cancer Center, shares his expert point of view on data presented on front-line therapies for chronic lymphocytic leukemia (CLL) presented at the 2025 ASCO Annual Meeting. 

Breast Cancer

Nicholas C. Turner, MD, PhD, on Treating Emergent ESR1 Mutations in Advanced Breast Cancer

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents findings from the phase III, double-blind ctDNA-guided SERENA-6 trial, which evaluated the combination of camizestrant plus a CDK4/6 inhibitor to treat emergent ESR1 mutations during first-line endocrine therapy for patients with HR-positive, HER2-negative advanced breast cancer (LBA4). 

Gynecologic Cancers

Alicia Latham, MD, MS, on Using ctDNA to Detect Endometrial Cancer

Alicia Latham, MD, MS, of Memorial Sloan Kettering Cancer Center, discusses the feasibility of using Pap-derived ctDNA for the detection of sporadic and Lynch syndrome–associated endometrial cancer (Abstract 10503). 

Advertisement

Advertisement




Advertisement